Literature DB >> 12619867

Cloning and bacterial expression of postnatal mouse heart FGF-16.

David P Sontag1, Peter A Cattini.   

Abstract

Fibroblast growth factor-16 (FGF-16) has been reported as the sixteenth member of the heparin sulphate proteoglycan binding growth factor family, which includes acidic and basic FGFs (FGF-1 and FGF-2), based on sequence similarity. The sequences of human (h) and rat (r) FGF-16 complimentary DNA (cDNA) sequences are known. Rat FGF-16 is expressed in brown adipose tissue during embryonic development but also shows some specificity for the postnatal heart. In spite of the importance of other FGF family members in cardiac physiology, there is scant information about FGF-16 function. As a first step towards exploiting mouse genetics in this regard, we have used reverse transcriptase-polymerase chain reaction and primers based on the rFGF-16 sequence to clone the adult mouse (m) FGF-16 cDNA. An mFGF-16 cDNA of 624 base pairs was generated. Based on sequence analysis, mFGF-16 and hFGF-16 share at least 95.2 and 99% nucleotide and amino acid similarity, respectively. In terms of other family members, FGF-16 is most closely related to FGF-9. When used as a radiolabeled probe, the mFGF-16 cDNA detected a single 1.8 kilobase transcript in adult mouse heart RNA. The mFGF-16 cDNA was also used to generate an amino-terminal poly-histidine tagged FGF-16 protein in bacteria. Using sodium dodecyl sulphate-polyacrylamide gel electrophoresis and taking into account the poly-histidine tag, an FGF-16 protein of 26.3 kDa was detected. The generation of cardiac mFGF-16 cDNA and a purified FGF-16 protein preparation are seen as important tools in the further characterization of FGF-16 expression and function in the mammalian heart.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12619867

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  32 in total

1.  Structure and expression of a novel member, FGF-16, on the fibroblast growth factor family.

Authors:  A Miyake; M Konishi; F H Martin; N A Hernday; K Ozaki; S Yamamoto; T Mikami; T Arakawa; N Itoh
Journal:  Biochem Biophys Res Commun       Date:  1998-02-04       Impact factor: 3.575

2.  Long-term outcome study of growth factor-treated pressure ulcers.

Authors:  W G Payne; D E Ochs; D D Meltzer; D P Hill; R J Mannari; L E Robson; M C Robson
Journal:  Am J Surg       Date:  2001-01       Impact factor: 2.565

3.  Requirement for BMP and FGF signaling during cardiogenic induction in non-precardiac mesoderm is specific, transient, and cooperative.

Authors:  M Barron; M Gao; J Lough
Journal:  Dev Dyn       Date:  2000-06       Impact factor: 3.780

Review 4.  Therapeutic angiogenesis for ischemic cardiovascular disease.

Authors:  S B Freedman; J M Isner
Journal:  J Mol Cell Cardiol       Date:  2001-03       Impact factor: 5.000

5.  Basic fibroblast growth factor is cardioprotective in ischemia-reperfusion injury.

Authors:  R R Padua; R Sethi; N S Dhalla; E Kardami
Journal:  Mol Cell Biochem       Date:  1995-02-23       Impact factor: 3.396

6.  Impaired cerebral cortex development and blood pressure regulation in FGF-2-deficient mice.

Authors:  R Dono; G Texido; R Dussel; H Ehmke; R Zeller
Journal:  EMBO J       Date:  1998-08-03       Impact factor: 11.598

7.  Adenoviral-mediated expression of antisense RNA to fibroblast growth factors disrupts murine vascular development.

Authors:  I Leconte; J C Fox; H S Baldwin; C A Buck; J L Swain
Journal:  Dev Dyn       Date:  1998-12       Impact factor: 3.780

8.  Activin-A and FGF-2 mimic the inductive effects of anterior endoderm on terminal cardiac myogenesis in vitro.

Authors:  Y Sugi; J Lough
Journal:  Dev Biol       Date:  1995-04       Impact factor: 3.582

9.  Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results.

Authors:  F W Sellke; R J Laham; E R Edelman; J D Pearlman; M Simons
Journal:  Ann Thorac Surg       Date:  1998-06       Impact factor: 4.330

10.  Therapeutic myocardial angiogenesis using percutaneous intrapericardial drug delivery.

Authors:  R J Laham; D Hung; M Simons
Journal:  Clin Cardiol       Date:  1999-01       Impact factor: 2.882

View more
  5 in total

1.  Restricted expression of Fgf16 within the developing chick inner ear.

Authors:  Susan C Chapman; Qin Cai; Steven B Bleyl; Gary C Schoenwolf
Journal:  Dev Dyn       Date:  2006-08       Impact factor: 3.780

2.  Involvement of FGF9/16/20 subfamily in female germ cell development of the Nile tilapia, Oreochromis niloticus.

Authors:  Yun-Lv Sun; Sheng Zeng; Kai Ye; Chao Yang; Ming-Hui Li; Bao-Feng Huang; Li-Na Sun; Lin-Yan Zhou; De-Shou Wang
Journal:  Fish Physiol Biochem       Date:  2012-03-27       Impact factor: 2.794

3.  FGF-16 protects against adverse cardiac remodeling in the infarct diabetic heart.

Authors:  Yanyan Hu; Li Li; Lin Shen; Haiqing Gao; Fei Yu; Wenbin Yin; Wei Liu
Journal:  Am J Transl Res       Date:  2017-04-15       Impact factor: 4.060

4.  Fgf16 is required for specification of GABAergic neurons and oligodendrocytes in the zebrafish forebrain.

Authors:  Ayumi Miyake; Tatsuya Chitose; Eriko Kamei; Atsuko Murakami; Yoshiaki Nakayama; Morichika Konishi; Nobuyuki Itoh
Journal:  PLoS One       Date:  2014-10-30       Impact factor: 3.240

5.  Fibroblast growth factor 9 (FGF9) inhibits myogenic differentiation of C2C12 and human muscle cells.

Authors:  Jian Huang; Kun Wang; Lora A Shiflett; Leticia Brotto; Lynda F Bonewald; Michael J Wacker; Sarah L Dallas; Marco Brotto
Journal:  Cell Cycle       Date:  2019-11-18       Impact factor: 4.534

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.